GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EGEIRO Pharma (XPAR:ALVET) » Definitions » Gross-Profit-to-Asset %

EGEIRO Pharma (XPAR:ALVET) Gross-Profit-to-Asset % : -8.88% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is EGEIRO Pharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. EGEIRO Pharma's annualized Gross Profit for the quarter that ended in Dec. 2023 was €-0.69 Mil. EGEIRO Pharma's average Total Assets over the quarter that ended in Dec. 2023 was €7.75 Mil. Therefore, EGEIRO Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was -8.88%.


EGEIRO Pharma Gross-Profit-to-Asset % Historical Data

The historical data trend for EGEIRO Pharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EGEIRO Pharma Gross-Profit-to-Asset % Chart

EGEIRO Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
0.05 -3.11 -7.29 -7.70 -6.23

EGEIRO Pharma Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.26 -5.03 -4.28 -8.88 10.54

Competitive Comparison of EGEIRO Pharma's Gross-Profit-to-Asset %

For the Biotechnology subindustry, EGEIRO Pharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EGEIRO Pharma's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EGEIRO Pharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where EGEIRO Pharma's Gross-Profit-to-Asset % falls into.


;
;

EGEIRO Pharma Gross-Profit-to-Asset % Calculation

EGEIRO Pharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-0.531/( (9.502+7.534)/ 2 )
=-0.531/8.518
=-6.23 %

EGEIRO Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-0.688/( (7.959+7.534)/ 2 )
=-0.688/7.7465
=-8.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


EGEIRO Pharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of EGEIRO Pharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


EGEIRO Pharma Business Description

Traded in Other Exchanges
N/A
Address
Avenue Jean Mermoz 32/1, Gosselies, BEL, 6041
EGEIRO Pharma is a biopharmaceutical company. The company is focused on the clinical development of drugs for Idiopathic Pulmonary Fibrosis, a chronic, devastating, and fatal disease characterized by the deterioration of lung function.

EGEIRO Pharma Headlines

No Headlines